Close Menu

People in the News

Jul 20, 2020

NeoGenomics:  Michael Kelly, Lynn Tetrault

NeoGenomics said Michael Kelly has joined its board of directors and Lynn Tetrault has been named lead independent director of the board.

Kelly joined the board on July 15 and will serve as a member of the audit committee. He is a former senior executive of Amgen and is currently acting as founder and president of Sentry Hill Partners. He has served in various strategic finance and operations positions at Amgen, most recently as senior vice president of global business services and VP and CFO of international commercial operations. Kelly has also held positions at Biogen, Tanox, and Monsanto Life Sciences.

Tetrault also assumed her new role as of July 15. She has served on the company’s board since June 2015 and is chair of the compensation committee. She founded Anahata Leadership, an advisory firm focused on supporting the leadership effectiveness of executive women. She worked from 1993 to 2014 with AstraZeneca, most recently on its global executive team as executive vice president of human resources and corporate affairs from 2007 to 2014. Prior to AstraZeneca, Tetrault practiced healthcare and corporate law at Choate, Hall and Stewart in Boston.

Jul 14, 2020

Pattern Bioscience: Nick Naclerio

Nick Naclerio is joining Pattern Bioscience's board of directors in conjunction with the company's recent Series B-1 funding round. He is a founding partner of Illumina Ventures and the former senior VP of corporate and venture development at Illumina.

Jun 24, 2020

Sera Prognostics: Thomas Garite

Sera Prognostics has appointed Thomas Garite its vice president of clinical sciences. He will work to advance the Salt Lake City-based firm's clinical development programs as Sera Prognostics moves into the commercial stage. Garite recently retired as the Edward H. Quilligan Professor of Obstetrics and Gynecology at the University of California, Irvine. He was the department's chairman for 18 years and is now professor emeritus. He also served as director of research and education for obstetrix at the MedNax Medical Group. He currently is chief clinical officer for patient safety company Perigen.

Jun 23, 2020

NeoGenomics: Cynthia Dieter

NeoGenomics announced the appointment of Cynthia Dieter as chief accounting officer and controller, effective June 22. Before coming to NeoGenomics, Dieter was the senior director of corporate accounting at Viasat. She has also served in multiple roles at DJO Global, including VP and assistant corporate controller, VP and vista controller, and director of financial reporting and planning. 

In addition, Dieter has been the manager of financial reporting at Captiva Software and audit manager for Ernst and Young. 

Jun 19, 2020

Guardant Health: Vijaya Gadde

Guardant Health has appointed Vijaya Gadde to serve on its Board of Directors. Gadde is Twitter's chief legal officer leading its legal, public policy, and trust and safety teams globally. Prior to joining Twitter in 2011, she was senior director, legal at Juniper Networks. Before that, she worked for nearly a decade at Wilson Sonsini Goodrich & Rosati. Gadde serves on the Board of Trustees of NYU Law School and the Board of Directors of Mercy Corps. She is also a co-founder of #Angels, an investment collective focused on funding diverse and ambitious founders pursuing bold ideas. She earned a JD from New York University School of Law and a BS in industrial and labor relations from Cornell University.

Jun 18, 2020

T2 Biosystems: Thierry Bernard, Ninfa Saunders, Robin Toft

T2 Biosystems has appointed Thierry Bernard, Ninfa Saunders, and Robin Toft to its board of directors. Bernard currently serves as CEO of Qiagen, Saunders is president and CEO of Navicent Health, and Toft is founder and CEO of Toft Group and previously served as senior vice president of commercial operations at Roche Molecular Diagnostics. T2 Biosystems also announced that Michael CimaAdrian Jones, and Stanley Lapidus will be leaving the firm's board of directors.

Jun 16, 2020

AACC: Stephen Master, Paul Jannetto, Christopher McCudden, Christine Schmotzer, Gyorgy Abel

The American Association for Clinical Chemistry announced that Stephen Master was elected to serve as president-elect in August 2020, after which he will serve as president from August 2021 to July 2022, and as past president from August 2022 to July 2023. Master is the chief of the division of laboratory medicine at the Children’s Hospital of Philadelphia and medical director of the Michael Palmieri Laboratory for Metabolic and Advanced Diagnostics at CHOP. He's also an associate professor of pathology and laboratory medicine at the Perelman School of Medicine, University of Pennsylvania. Master is currently a member of the organization's board of directors. 

AACC also announced Paul Jannetto would serve as secretary from August 2020 to July 2023. Jannetto is an associate professor of laboratory medicine and pathology at the Mayo Clinic, as well as the co-director for the clinical mass spectrometry laboratory, clinical and forensic toxicology laboratory, and the metals laboratory. He has previously served on the AACC and AACC Academy boards, chair and secretary of the AACC Chicago Local Section, and treasurer of AACC's Midwest Local Section. 

The organization announced Christopher McCudden and Christine Schmotzer as new board members, serving from August 2020 to July 2023, and Gyorgy Abel as president of AACC Academy, who will also sit on the board. McCudden is a clinical biochemist at the Ottawa Hospital in Ontario, Canada, and an associate professor and vice chair of the department of pathology and laboratory medicine at the University of Ottawa. 

Schmotzer is chief of the division of clinical pathology and medical director of laboratories and point-of-care testing at University Hospitals Cleveland Medical Center. She is also co-director of the University Hospitals Diagnostic Institute and an associate professor of pathology at Case Western Reserve University. 

Jun 15, 2020

Laboratory for Advanced Medicine: Samuel Tong

Laboratory for Advanced Medicine has appointed Samuel Tong as CEO for its operations in China. He joins the company from medical research organization NAMSA where he was vice president and general manager of the Asia-Pacific region. Prior to that, he was VP and GM for greater China at Qiagen. Tong was also business unit director of diagnostics systems for greater China at Becton Dickinson, and country manager of China at Abbott Vascular.

Jun 15, 2020

Foundation Medicine: Geoffrey Oxnard

Roche subsidiary Foundation Medicine announced Geoffrey Oxnard has been appointed vice president, global medical lead for the firm's liquid biopsy portfolio, effective immediately. In the role, he'll define research and a liquid biopsy-focused discovery roadmap while investigating novel applications of liquid biopsy approaches to improve cancer research and care.

Oxnard previously served as a thoracic oncologist and clinical investigator at the Dana-Farber Cancer Institute at Harvard Medical School, and he'll continue seeing patients part-time at the institute. His recent research has focused on the clinical application of liquid biopsy technologies to understand drug resistance for selecting targeted therapies and detecting occult cancer. 

Jun 12, 2020

Scipher Medicine: Jerry Conway

Scipher Medicine has named Jerry Conway as senior vice president of market access. He will focus on patient access to Scipher's precision diagnostic tools beginning with PrismRA, a molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid arthritis, and is slated to launch later this year. Conway most recently served as executive vice president at CDx Diagnostics.

Jun 12, 2020

AACC: Mark Golden

Mark Golden has been appointed the CEO of the American Association for Clinical Chemistry, effective Aug. 17. Prior to joining AACC, he was executive director and CEO of the National Society of Professional Engineers for seven years. AACC had previously said that its current CEO Janet Kreizman would retire from the organization.

Jun 11, 2020

Quidel: Jack Schuler

Jack Schuler has retired from Quidel's board, effective June 10, the firm said. Schuler, 79, has been on Quidel's board since February 2006. He was the former president and chief operating officer of Abbott Laboratories.

Jun 04, 2020

Viracor, Transplant Genomics: John Holman, Roz Mannon, Michael Abecassis, Fuad Shihab, Win Williams, Anil Chandraker, Allan Kirk, Jonathan Bromberg, Robert Fairchild, Matt Cooper

Transplant Genomics (TGI) and Viracor Eurofins announced that they have formed the Eurofins Transplant medical and scientific advisory board, which will be convened by Eurofins TGI's VP of Medical Affairs John Holman. The board will include Roz Mannon, University of Nebraska; Michael Abecassis, University of Arizona; Fuad Shihab, University of Utah; Win Williams, Massachusetts General Hospital; Anil Chandraker, Brigham and Women's Hospital; Allan Kirk, Duke University; Jonathan Bromberg, University of Maryland; Robert Fairchild, Cleveland Clinic; and Matt Cooper, Georgetown University.

The board consists of people with diverse expertise and experience in transplantation technology development and clinical studies, and will be tasked with providing independent advice on unmet clinical needs in transplantation to guide the evolution of TGI and Viracor's current and future products that expand the indications for its TruGraf and Trac product lines through clinical studies. The board will also provide advice on R&D or acquisition of additional disruptive technologies for the Eurofins transplant portfolio.

Jun 04, 2020

NeoGenomics: Rachel Stahler

NeoGenomics announced Rachel Stahler would join the company's board of directors, effective immediately. She will serve on the board's audit committee. Stahler was recently named the chief information officer for Merck's intended women's health and biosimilars spinoff Organon & Co. Previously, she was the CIO at pharmaceuticals firm Allergan, Syneos Health, and Optimer Pharmaceuticals. 

Jun 02, 2020

Chembio Diagnostics: Chuck Caso

Chembio Diagnostics has appointed Chuck Caso as its vice president of sales and marketing for North America with responsibility for direct and channel sales efforts throughout the region.

Caso brings more than 20 years of diagnostics industry experience to his new role. He has served in various executive sales and marketing roles at Meridian Biosciences, Quest Diagnostics, and Danaher.

May 29, 2020

OraSure Technologies: Lelio Marmora

OraSure Technologies has appointed Lelio Marmora as a member of the company's board of directors, effective June 1. Marmora previously served as executive director of Unitaid and also held senior positions at the Global Fund to Fight AIDS, TB and, Malaria.

May 29, 2020

Castle Biosciences: Federico Monzon

In a filing with the US Securities and Exchange Commission, Castle Biosciences said that Chief Medical Officer Federico Monzon notified the company on May 21 that he plans to resign, effective May 31. In November 2019, the firm had disclosed Monzon's intention to resign on or about April 1, 2020, but the move was subsequently delayed. 

May 28, 2020

Gradientech: Gisela Sitbon, Rolf Ehrnström, Simon Turner

Gradientech has added three new board members: Gisela Sitbon, Rolf Ehrnström, and Simon Turner. Sitbon boasts more than 25 years of senior level life science experience and will be the new chair of the board at the Uppsala, Sweden-based developer of rapid phenotypic antibiotic suceptibility testing. Ehrnström, meanwhile, has experience in research and development at companies such as Amersham Pharmacia Biotech, Dako, and Gyros, while Turner is an investment analyst.

May 28, 2020

First Light Diagnostics: Andrew Wilsack

First Light Diagnostics has appointed Andrew Wilsack its CFO. He has more than 25 years of experience in the life science industry, including most recently as a financial consultant at Danforth Advisors. Previously, he was vice president of FPA at Masimo and CFO at Argose. 

May 28, 2020

Myriad Genetics: John Henderson, Daniel Spiegelman

Myriad Genetics said that John Henderson will retire from its board of directors at its annual meeting in December. Henderson chaired the board from April 2005 through March 2020, at which point Louise Phanstiel was elected to serve as chair. The company has also elected to its board of directors Daniel Spiegelman, who was most recently executive VP and CFO of BioMarin Pharmaceuticals. After retiring from that role, Spiegelman has been serving on the board of Tizona Therapeutics, as well on the boards of several biotech firms.

May 27, 2020

AXIM Biotechnologies: Sergei Svarovsky

AXIM Biotechnologies has appointed Sergei Svarovsky as the CSO of subsidiary Sapphire Biotech. Svarovsky previously served as a research fellow at the National Institute of Health's National Cancer Institute. AXIM noted that Svarovsky has experience with cancer drug design medical diagnostics develompent, including developing a wide range of biological assays for existing and novel platforms for many well-known biotech firms. 

May 26, 2020

Progenity: Damon Silvestry

Molecular testing firm Progenity has appointed Damon Silvestry as its chief operating officer. Silvestry has more than 15 years of experience in strategic lab and business operations, including stints at Natera, Miraca Life Sciences, and Dell. He was most recently senior vice president, operations and people office at Natera.

May 26, 2020

Proteomedix: Maurizo Ballerini, Helene Peyro Saint-Paul

Swiss cancer diagnostics company Proteomedix has appointed Maurizo Ballerini as vice president of market development for Europe, the Middle East, and Africa, and Helene Peyro Saint-Paul as medical advisor. Both appointments are effective June 1. Ballerini has held medical, commercial, and management positions with MDxHealth, GenProbe, now part of Hologic, Stryker, Randox Laboratories, and Abbott Laboratories. Peyro Saint-Paul has held corporate leadership positions at Serono, Ipsogen, and Qiagen. 

May 26, 2020

Freenome: Bill Quirk, Gary Reedy

Freenome has hired Bill Quirk as its CFO. Prior to joining Freenome, Quirk served as a managing director in the equity research division of investment bank Piper Sandler. The company also announced that Gary Reedy has joined its board of directors as an observer. Reedy became CEO of the American Cancer Society in April 2015, having worked with the organization for more than 20 years. He has had a 37-year career as a healthcare business and advocacy leader, most recently as worldwide VP of government affairs and policy at Johnson & Johnson. He also held senior leadership positions with SmithKline Beecham, Centocor, and Johnson & Johnson.

May 20, 2020

Meridian Bioscience: Tony Serafini-Lamanna

Meridian Bioscience promoted Tony Serafini-Lamanna to executive VP of diagnostics, passing responsibility of the diagnostics division from CEO Jack Kenny and making Serafini-Lamanna an officer of the company. He was previously the global VP and general manager of diagnostics, a position he held since April 2018. The promotion became effective May 18. 

Before joining Meridian, Serafini-Lamanna worked at Siemens Healthcare Diagnostics as general manager for diagnostics Canada and VP of marketing for North America. 

Pages